Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer

NCT00005032 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT00005032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer
Lead sponsor
University of Chicago
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2000
Completion date
September 30, 2001
Enrollment
12 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer